Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 14/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2523911 | 1.00 | SLC6A4 (0.53) | SLC6A4SLC6A2SLC6A3LMNACHRM2 | |
| SCHEMBL2523957 | 1.00 | SLC6A4 (0.53) | SLC6A4SLC6A2SLC6A3LMNACHRM2 | |
| SCHEMBL16657611 | 0.82 | SLC6A4 (0.73) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL3405447 | 0.79 | KDM4E (0.47) | SLC6A4SLC6A2SLC6A3LMNACHRM2 | |
| SCHEMBL14980395 | 0.79 | SLC6A2 (0.58) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL14090989 | 0.77 | SLC6A4 (0.71) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL23532373 | 0.71 | RPS6KB1 (0.54) | RPS6KB1 | |
| SCHEMBL29894639 | 0.70 | RPS6KB1 (0.53) | RPS6KB1 | |
| SCHEMBL3895066 | 0.70 | SLC6A2 (0.75) | SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL27808050 | 0.68 | SLC6A4 (0.47) | SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328091-B2 | 5H-cyclopenta[d]pyrimidines as AKT protein kinase inhibitors | GENENTECH, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150266852-A1 | 5H-CYCLOPENTA[d]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. | 2015-09-24 | — | — | US | disclosed |
| US-8895566-B2 | 5H-cyclopenta[d]pyrimidines as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-11-25 | — | — | US | disclosed |
| EP-2250155-B1 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20130085135-A1 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-04-04 | — | — | US | disclosed |
| US-8329709-B2 | 5H-cyclopenta[D]pyrimidines as AKT protein kinase inhibitors | GENENTECH, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| EP-1848719-B1 | [1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-YL]-PIPERIDINE OR -PIPERAZINE COMPOUNDS AS SERINE-THREONINE KINASE MODULATORS (P70S6K, ATK1 AND ATK2) FOR THE TREATMENT OF IMMUNOLOGICAL, INFLAMMATORY AND PROLIFERATIVE DISEASES | EXELIXIS INC (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20110251181-A1 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-7994172-B2 | [1-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl](4-chlorophenyl)methanol; kinase-dependent diseases, invasive cell growth, and metabolism | EXELIXIS, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-7994172-B2 | [1-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl](4-chlorophenyl)methanol; kinase-dependent diseases, invasive cell growth, and metabolism | EXELIXIS, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| EP-2250155-A1 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009089462-A1 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20080188482-A1 | [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases | EXELIXIS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080188482-A1 | [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases | EXELIXIS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188482-A1 | [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases | PDPK1, MTOR, RPS6KA2 | SLC6A4 4294/4885SLC6A2 4586/4885SLC6A3 4435/4885 |
| US-20150266852-A1 | 5H-CYCLOPENTA[d]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | PIK3CA, AKT3, AKT2 | SLC6A4 3196/4885SLC6A2 3899/4885SLC6A3 3700/4885 |
| US-20130085135-A1 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | PIK3CA, AKT3, AKT2 | SLC6A4 3196/4885SLC6A2 3899/4885SLC6A3 3700/4885 |
| US-20110251181-A1 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | AKT3, PIK3CA, AKT2 | SLC6A4 3302/4885SLC6A2 4078/4885SLC6A3 3828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.